Aligos therapeutics announces $92 million private placement financing

Proceeds expected to fund the following: - nash (alg-055009): top line data from phase 2a study (q4 2024) - hepatitis b/cam-e (alg-000184): phase 2 enabling activities (h2 2024) - funding expected to extend cash runway through end of 2025

ALGS Ratings Summary

ALGS Quant Ranking